Data from: Assessment of markers of antimalarial drug resistance in Plasmodium falciparum isolates from pregnant women in Lagos, Nigeria
Background: The use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Although sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used drugs...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Dataset |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: The use of antimalarial drugs for prevention and treatment is
a major strategy in the prevention of malaria in pregnancy. Although
sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent
preventive treatment of malaria during pregnancy in Nigeria, previously
used drugs for prophylaxis such as chloroquine (CQ) and pyrimethamine are
accessible as they are purchased over the counter. This study describes
the markers of absence or presence of resistance to quinoline (Pfcrt and
Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr). Methods:
Plasmodium falciparum-positive dried blood spots from pregnant women
attending antenatal clinics for the first time during current pregnancy
were investigated for the presence of mutations at codons 72–76 of
Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene by
real time polymerase chain reaction (PCR) using haplotype-specific probes.
PCR followed by sequence analysis was used to identify mutations at codons
86, 184, 1034, 1042 and 1246 of P. falciparum multi-drug resistance-1
(Pfmdr1) gene; and codons 16, 50, 51, 59, 108, 140 and 164 of Pfdhfr gene.
Results: Two haplotypes of Pfcrt (n = 54) were observed: CVMNK 13(24.2%)
and CVIET 41 (75.9%) of the samples. The SVMNT haplotype was absent in
this population. The Pfmdr1 (n = 28) haplotypes were NYSND 15(53.6%),
YYSND 5(17.9%), NFSND 6(21.4%) and YFSND 2(7.1%). The Pfdhfr (n = 15) were
ACNCSVI 4(26.7%), and ACICNSVI 1(6.7%) and ACIRNVI 10 (66.7%). The rate of
occurrence of Pfcrt 76T, Pfdhfr108N, Pfmdr186Yand184F were 75.9%, 73.3%,
25% and 28.1% respectively. The Pfmdr1 86Y was associated with low
parasitaemia (median = 71 parasites/μl, P = 0.024) while Pfcrt 76T was
associated with young maternal age (mean 24.1 ± 4.5 years; P = 0.006). The
median parasitaemia were similar (P>0.05) in wild and mutant
strains of Pfcrt 76, Pfmdr1 184 and Pfdhfr 108. There was no association
between gravidity or gestational age of the women and presence of
mutations in the Pfcrt, Pfmdr1 or Pfdhfr genes (P>0.05).
Conclusion: Markers of resistance to chloroquine and pyrimethamine were
high, whereas cycloguanil-resistance marker was not present in the studied
population. The low level of mutations in the Pfmdr1gene indicates likely
efficacy of amodiaquine against malaria in pregnancy. |
---|---|
DOI: | 10.5061/dryad.b3f50 |